共 157 条
[1]
Ansell SM(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 372 311-319
[2]
Lesokhin AM(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N Engl J Med 375 1856-1867
[3]
Borrello I(2015)Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 372 2018-2028
[4]
Halwani A(2015)Combined nivolumab and ipilimumab or monotherapy in untreated melanoma N Engl J Med 373 23-34
[5]
Scott EC(2015)Nivolumab versus everolimus in advanced renal-cell carcinoma N Engl J Med 373 1803-1813
[6]
Gutierrez M(2017)Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Lancet Oncol 18 1182-1191
[7]
Ferris RL(2019)Immunotherapy of melanoma: facts and hopes Clin Cancer Res 25 5191-5201
[8]
Blumenschein G(2016)The future of cancer treatment: immunomodulation, CARs and combination immunotherapy Nat Rev Clin Oncol 13 394-571
[9]
Fayette J(2014)PD-1 blockade induces responses by inhibiting adaptive immune resistance Nature. 515 568-123
[10]
Guigay J(2019)Clinical-grade N-(4-[ EJNMMI Radiopharm Chem 4 15-190